^
Association details:
| Biomarker: | EGFR mutation + MET Y1003N |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Osimertinib and capmatinib combination therapy to overcome MET Y1003N-mediated resistance in EGFR-mutant NSCLC: A Case Report
Published date:
08/04/2022
Excerpt:
...we present the case of a 65-year-old female with metastatic EGFR-mutant NSCLC whose disease progressed on osimertinib due to emergence of MET Y1003N mutation. She subsequently received capmatinib in combination with osimertinib and achieved a partial response.
DOI:
https://doi.org/10.1016/j.jtocrr.2022.100396
